These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7585041)

  • 101. The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of
    Ainatzoglou A; Stamoula E; Dardalas I; Siafis S; Papazisis G
    Curr Pharm Des; 2021; 27(20):2387-2397. PubMed ID: 33655851
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.
    Sommer N; Martin R; McFarland HF; Quigley L; Cannella B; Raine CS; Scott DE; Löschmann PA; Racke MK
    J Neuroimmunol; 1997 Oct; 79(1):54-61. PubMed ID: 9357447
    [TBL] [Abstract][Full Text] [Related]  

  • 103. FDA-approved PDE4 inhibitors alleviate the dominant toxicity of ALS-FTD-associated CHCHD10S59L by reducing the PINK1/Parkin pathway.
    Maitra S; Baek M; Choe YJ; Kim NC
    Res Sq; 2024 Sep; ():. PubMed ID: 39315251
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Continuous-Flow Chemistry and Photochemistry for Manufacturing of Active Pharmaceutical Ingredients.
    Horáková P; Kočí K
    Molecules; 2022 Dec; 27(23):. PubMed ID: 36500629
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Emerging Potential of the Phosphodiesterase (PDE) Inhibitor Ibudilast for Neurodegenerative Diseases: An Update on Preclinical and Clinical Evidence.
    Angelopoulou E; Pyrgelis ES; Piperi C
    Molecules; 2022 Dec; 27(23):. PubMed ID: 36500540
    [TBL] [Abstract][Full Text] [Related]  

  • 106. An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.
    Crocetti L; Floresta G; Cilibrizzi A; Giovannoni MP
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956914
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Pharmacokinetic/Pharmacodynamic Evaluation of a New Purine-2,6-Dione Derivative in Rodents with Experimental Autoimmune Diseases.
    Świerczek A; Pociecha K; Plutecka H; Ślusarczyk M; Chłoń-Rzepa G; Wyska E
    Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631676
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Direct β-selectivity of α,β-unsaturated γ-butyrolactam for asymmetric conjugate additions in an organocatalytic manner.
    Zhong Y; Hong S; Cai Z; Ma S; Jiang X
    RSC Adv; 2018 Aug; 8(51):28874-28878. PubMed ID: 35548007
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Enantioselective Flow Synthesis of Rolipram Enabled by a Telescoped Asymmetric Conjugate Addition-Oxidative Aldehyde Esterification Sequence Using
    Nagy BS; Llanes P; Pericas MA; Kappe CO; Ötvös SB
    Org Lett; 2022 Feb; 24(4):1066-1071. PubMed ID: 35050638
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Transcriptional Factors and Protein Biomarkers as Target Therapeutics in Traumatic Spinal Cord and Brain Injury.
    Kumar S; Fritz Z; Sulakhiya K; Theis T; Berthiaume F
    Curr Neuropharmacol; 2020; 18(11):1092-1105. PubMed ID: 32442086
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Transcription factors Tp73, Cebpd, Pax6, and Spi1 rather than DNA methylation regulate chronic transcriptomics changes after experimental traumatic brain injury.
    Lipponen A; El-Osta A; Kaspi A; Ziemann M; Khurana I; Kn H; Navarro-Ferrandis V; Puhakka N; Paananen J; Pitkänen A
    Acta Neuropathol Commun; 2018 Feb; 6(1):17. PubMed ID: 29482641
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays.
    de Medeiros AS; Wyman AR; Alaamery MA; Allain C; Ivey FD; Wang L; Le H; Morken JP; Habara A; Le C; Cui S; Lerner A; Hoffman CS
    Cell Signal; 2017 Dec; 40():73-80. PubMed ID: 28867658
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury.
    Wilson NM; Gurney ME; Dietrich WD; Atkins CM
    PLoS One; 2017; 12(5):e0178013. PubMed ID: 28542295
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Efficient Synthesis of β-Aryl-γ-lactams and Their Resolution with (S)-Naproxen: Preparation of (R)- and (S)-Baclofen.
    Montoya-Balbás IJ; Valentín-Guevara B; López-Mendoza E; Linzaga-Elizalde I; Ordoñez M; Román-Bravo P
    Molecules; 2015 Dec; 20(12):22028-43. PubMed ID: 26690390
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Pharmacological implications of the Ca(2+)/cAMP signaling interaction: from risk for antihypertensive therapy to potential beneficial for neurological and psychiatric disorders.
    Caricati-Neto A; García AG; Bergantin LB
    Pharmacol Res Perspect; 2015 Oct; 3(5):e00181. PubMed ID: 26516591
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Flow "Fine" Synthesis: High Yielding and Selective Organic Synthesis by Flow Methods.
    Kobayashi S
    Chem Asian J; 2016 Feb; 11(4):425-36. PubMed ID: 26337828
    [TBL] [Abstract][Full Text] [Related]  

  • 117. PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis.
    Mestre L; Redondo M; Carrillo-Salinas FJ; Morales-García JA; Alonso-Gil S; Pérez-Castillo A; Gil C; Martínez A; Guaza C
    Br J Pharmacol; 2015 Sep; 172(17):4277-90. PubMed ID: 25994655
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Multistep continuous-flow synthesis of (R)- and (S)-rolipram using heterogeneous catalysts.
    Tsubogo T; Oyamada H; Kobayashi S
    Nature; 2015 Apr; 520(7547):329-32. PubMed ID: 25877201
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.
    Titus DJ; Oliva AA; Wilson NM; Atkins CM
    Curr Pharm Des; 2015; 21(3):332-42. PubMed ID: 25159077
    [TBL] [Abstract][Full Text] [Related]  

  • 120. The TLR and IL-1 signalling network at a glance.
    Cohen P
    J Cell Sci; 2014 Jun; 127(Pt 11):2383-90. PubMed ID: 24829146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.